Trials / Active Not Recruiting
Active Not RecruitingNCT06540261
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
An Open-label, Uncontrolled Study of ONO-7913, ONO-4538 and the Standard of Care FOLFOX in Combination With Bevacizumab or Cetuximab as First-line Treatment in Patients With Unresectable Advanced or Recurrent Colorectal Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7913 | Specified dose on specified days |
| DRUG | ONO-4538 | Specified dose on specified days |
| DRUG | Fluorouracil | Specified dose on specified days |
| DRUG | Oxaliplatin | Specified dose on specified days |
| DRUG | Levofolinate | Specified dose on specified days |
| DRUG | Bevacizumab | Specified dose on specified days |
| DRUG | Cetuximab | Specified dose on specified days |
Timeline
- Start date
- 2021-09-23
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2024-08-06
- Last updated
- 2024-09-19
Locations
17 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06540261. Inclusion in this directory is not an endorsement.